TransTech Pharma, Inc. Release: Novel, Oral Drug TTP488 Shows Promise for Disease Modification in Alzheimer’s Patients
10/29/2012 2:38:56 PM
HIGH POINT, N.C.--(BUSINESS WIRE)--A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer’s disease. TTP488 is a small-molecule drug that is the first to show clinical benefit from research on the receptor for advanced glycation endproducts (RAGE), a new biochemical target in Alzheimer’s disease treatment. TransTech Pharma, Inc. of High Point, North Carolina discovered, developed and owns all rights to this drug candidate.